Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches

Autor: Paraskevi Pnevmatikou, Charlotte Keywood, Elsa Melloni, Daniele Colombo

Publikováno v: Expert review of neurotherapeutics. 20(10)

Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting more than 10 million patients worldwide. Despite increasing improvements in disease management, a huge medical need still exists as its relentless progression can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c445b1a7db4696ea43a75d982651351
https://pubmed.ncbi.nlm.nih.gov/32758042

Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo

Autor: Maria Rosaria Carratù, Concetta Altamura, Gloria Padoani, Paola Imbrici, Elsa Melloni, Michela De Bellis, Sabata Pierno, Alessandro Farinato, Jean-François Desaphy, Silvia Vailati, Charlotte Keywood, Diana Conte, Nancy Tarantino, Annamaria De Luca, Carla Caccia

Publikováno v: Experimental neurology. 328

The antiarrhythmic sodium-channel blocker mexiletine is used to treat patients with myotonia. However, around 30% of patients do not benefit from mexiletine due to poor tolerability or suboptimal response. Safinamide is an add-on therapy to levodopa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7cd6d8e3ac70513aeaadd15d2400600
https://pubmed.ncbi.nlm.nih.gov/32205118

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Autor: Jean-Christophe Corvol, Stuart Isaacson, Charlotte Keywood, Sonia-Maria Poli, Mark F. Lew, François Tison, Mark Wakefield, Karla Eggert, Franck Durif, Claudia Trenkwalder, Olivier Rascol, Christopher G. Goetz, Erwan Bezard

Publikováno v: Movement Disorders. 31:1373-1380

Background The metabotropic glutamate receptor 5-negative allosteric modulator dipraglurant reduces levodopa-induced dyskinesia in the MPTP-macaque model. The objective of this study was to assess the safety, tolerability (primary objective), and eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc4a8ca633025a192d4ec87d29b28295
https://doi.org/10.1002/mds.26659

Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia

Autor: Elsa Melloni, James Kulisevsky, Clarissa Anna Pisanò, Michele Morari, Fabrizio Gardoni, Gloria Padoani, Carla Caccia, Salvatore Novello, Andrea Brugnoli, Silvia Vailati, Manuela Mellone, Victoria Sosti, Charlotte Keywood

Publikováno v: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy. In addition to its selective and reversible monoamine oxidase B inhibiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc02a2db0fac79c4b675cfa5e65c4499
https://pubmed.ncbi.nlm.nih.gov/30291173

Safinamide effects on skeletal muscle sodium channels and models of non-dystrophic myotonia (NDM) compared to mexiletine: Exploring potential for clinical utility

Autor: M. De Bellis, Sabata Pierno, Silvia Vailati, Diana Conte, Jean-François Desaphy, Paola Imbrici, Carla Caccia, Gloria Padoani, Elsa Melloni, Alessandro Farinato, Concetta Altamura, Charlotte Keywood

Publikováno v: Journal of the Neurological Sciences. 405:10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bf9db2aceb1cfbabe38cf1f90fc9944
https://doi.org/10.1016/j.jns.2019.10.435